TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06510140

Intervention type: BEHAVIORAL
Intervention: Detection of the Post-operative delirium (POD)
Description: Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).

Intervention type: BEHAVIORAL
Intervention: Detection of the Post-operative delirium (POD)
Description: Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
Study: NCT05370378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hold Relax with Agonist Contraction
Description: 1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Release Therapy
Description: 1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness
Study: NCT04354675

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Automated program (ChatBot)
Description: Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetics counselor
Description: Traditional in-person genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCGCKQ Survey
Description: Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BCGCKQ Survey
Description: Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction Survey
Description: Survey assessing satisfaction with Decision-Genetic Testing
Study: NCT05600114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: CBD 150 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: CBD 300 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT06207578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement using crestal sinus approach
Description: a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement using osseodensification
Description: The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
Study: NCT04636138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
Study: NCT06081985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with double-cone coil
Description: Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with sham coil
Description: Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
Study: NCT05980507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI201
Description: ICI201 CAR-T cell injection
Study: NCT06642584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B
Description: Semaglutide B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B
Description: Semaglutide B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B
Description: Semaglutide B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B
Description: Semaglutide B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B
Description: Semaglutide B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B
Description: Semaglutide B will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Semaglutide J will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Semaglutide J will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Semaglutide J will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Semaglutide J will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Semaglutide J will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Semaglutide J will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide L
Description: Semaglutide L will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide L
Description: Semaglutide L will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide M
Description: Semaglutide M will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide M
Description: Semaglutide M will be administered as oral tablets.
Study: NCT04354675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction Survey
Description: Survey assessing satisfaction with Decision-Genetic Testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genetic testing
Description: Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
Study: NCT06272084

Intervention type: DEVICE
Intervention: Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO
Description: Retrospective Data Analysis of TPE treatments with multiFiltratePRO
Study: NCT05602571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT+Exercise
Description: Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP+ESWT+Exercise
Description: Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham PRP+ESWT+Exercise
Description: Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).
Study: NCT05967689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS6417
Description: Oral tablets/capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS6417
Description: Oral tablets/capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS6417
Description: Oral tablets/capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS6417
Description: Oral tablets/capsules
Study: NCT05299996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flexible ureterorenoscopy
Description: stone disintegration stricture dilation tumor resection access guidance
Study: NCT05605314

Intervention type: OTHER
Intervention: Cyclosporine
Description: eye drop

Intervention type: OTHER
Intervention: Cyclosporine
Description: eye drop
Study: NCT05814978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Scapular Therapeutic Exercise Group
Description: All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions.
Study: NCT06454448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab;decitabine;
Description: Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
Study: NCT06052254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 cm2 - 2 Active DMTS Patches
Description: 2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 cm2 - 1 Active and 1 Placebo DMTS Patches
Description: 1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - 2 Placebo DMTS Patches
Description: 2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Study: NCT06152835

Intervention type: OTHER
Intervention: Data and breast milk samples collection
Description: Breast milk samples and, clinical, anamnestic and lifestyle data collection
Study: NCT06164496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standart manual toothbrush
Description: Device on plaque removal efficacy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 360 degree toothbrush
Description: Device on plaque removal efficacy
Study: NCT05816512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nano particle from Pelargonium Graveolens Mouthwash
Description: Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash .
Description: Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
Study: NCT05964465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Monoclonal antibody blocking interleukin 4 and interleukin 13
Study: NCT05523128

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ZS802
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
Study: NCT05981417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise sessions will be guided by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: Therapeutic exercise sessions will be performed at home.
Study: NCT06404216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking group training
Description: 16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged.
Study: NCT05887726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v d0(21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
Study: NCT06642584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide N
Description: Semaglutide N will be administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide N
Description: Semaglutide N will be administered as oral tablets.
Study: NCT05887726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg p.o d1-d5 (21-day cycles)
Study: NCT06152978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Study: NCT06515873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
Study: NCT05105750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 100 mg/d
Description: 100mg aspirin for at least 3 days followed by aspirin 100 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indobufen 200 mg bid
Description: 100mg aspirin for at least 3 days followed by indobufen 200 mg bid
Study: NCT04991727

Intervention type: BEHAVIORAL
Intervention: recruitment maneuvers
Description: Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery

Intervention type: BEHAVIORAL
Intervention: recruitment maneuvers
Description: Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery
Study: NCT05774054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: noradrenaline
Description: received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
Study: NCT04774536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRISPR_SCD001
Description: CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT06416657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different anesthesia methods, namely local anesthesia and general anesthesia
Description: Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different anesthesia methods, namely local anesthesia and general anesthesia
Description: Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants.
Study: NCT04961541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
Study: NCT06407804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrower's Ten Exercise Program
Description: No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine physical therapy.
Description: In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)
Study: NCT06510608

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical analysis of saliva sample
Description: It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
Study: NCT04961541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
Study: NCT06510608

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical analysis of saliva sample
Description: It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical analysis of saliva sample
Description: It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.